Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)
- PMID: 7827235
- DOI: 10.1007/BF01831376
Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)
Abstract
This study examines the relationship between menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer, focusing on whether associations differ according to whether the tumors are in situ or invasive. Data are from a prospective study conducted 1980-89 on 49,017 selected participants in the Breast Cancer Detection Demonstration Project, a five-year screening program conducted between 1973 and 1980 in the United States. Overall, the rate ratio for estrogen-only use compared with no-hormone use was 1.0, and that for the estrogen-progestin combination was 1.2 (95 percent confidence interval [CI] = 1.0-1.6). However, the associations differed according to whether the tumors were in situ or invasive. The rate ratios of in situ breast cancer associated with use of estrogens alone and the combination regimen were 1.4 (CI = 1.0-2.0) and 2.3 (CI = 1.3-3.9), respectively. Duration of estrogen-only use also was associated with risk of in situ tumors, with users for 10 or more years at twice the risk of nonusers (P-value for trend test = 0.02). Duration of use was not associated with risk of invasive cancer. Our results are consistent with the hypothesis that hormone replacement therapy is related to earlier-stage breast cancer; however, the possibility that the results reflect increased breast cancer surveillance among those taking hormones cannot be ruled out.
Similar articles
-
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.JAMA. 2000 Jan 26;283(4):485-91. doi: 10.1001/jama.283.4.485. JAMA. 2000. PMID: 10659874
-
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.N Engl J Med. 1995 Jun 15;332(24):1589-93. doi: 10.1056/NEJM199506153322401. N Engl J Med. 1995. PMID: 7753136
-
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.J Natl Cancer Inst. 2013 Apr 17;105(8):526-35. doi: 10.1093/jnci/djt043. Epub 2013 Mar 29. J Natl Cancer Inst. 2013. PMID: 23543779 Free PMC article.
-
Changing concepts: Menopausal hormone therapy and breast cancer.J Natl Cancer Inst. 2012 Apr 4;104(7):517-27. doi: 10.1093/jnci/djs014. Epub 2012 Mar 16. J Natl Cancer Inst. 2012. PMID: 22427684 Free PMC article. Review.
-
Breast cancer risk with postmenopausal hormonal treatment.Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. doi: 10.1093/humupd/dmi028. Epub 2005 Sep 8. Hum Reprod Update. 2005. PMID: 16150813 Review.
Cited by
-
Disparities in mammographic screening for Asian women in California: a cross-sectional analysis to identify meaningful groups for targeted intervention.BMC Cancer. 2007 Oct 26;7:201. doi: 10.1186/1471-2407-7-201. BMC Cancer. 2007. PMID: 17961259 Free PMC article.
-
Menopausal hormones and breast cancer in a biracial population.Am J Public Health. 2000 Jun;90(6):966-71. doi: 10.2105/ajph.90.6.966. Am J Public Health. 2000. PMID: 10846517 Free PMC article.
-
Targeted therapy for breast cancer prevention.Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250. Front Oncol. 2013. PMID: 24069582 Free PMC article. Review.
-
Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies.PLoS Med. 2014 Jul 8;11(7):e1001673. doi: 10.1371/journal.pmed.1001673. eCollection 2014 Jul. PLoS Med. 2014. PMID: 25003901 Free PMC article.
-
Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients.Br J Cancer. 1999 Jul;80(9):1453-8. doi: 10.1038/sj.bjc.6690543. Br J Cancer. 1999. PMID: 10424750 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical